Abstract: Neuronal survival after ischemic injury is determined through the induction of several biological pathways. We examined whether lubeluzole, an agent efficacious in both clinical and experimental models of cerebral ischemia, modulated the signal transduction mechanisms of nitric oxide (NO), a downstream mediator of anoxic neurodegeneration. Both pretreatment [NO survival = 23 ±3%, NO/lubeluzole (750 nM) survival = 63 ±2%, p <0.001] and coadministration [NO survival = 25 ±3%, NO/lubeluzole (750 nM) survival = 59 ±3%, p < 0.001] of lubeluzole with NO generators equally protected cultured hippocampal neurons in a dose-dependent manner against the toxic effects of NO, suggesting that the agent protects by acutely modifying toxic cellular pathways rather than preconditioning the neuron before injury. The protection observed with lubeluzole was stereospecific but was not limited to pre-or coadministration. Lubeluzole also was found to significantly protect against the toxicity of NO for a period of 4-6 h after NO exposure [NO survival = 31 ±2%, NO/lubeluzole (750 nM) survival at 6 h = 56 ±3%, p < 0.001]. We conclude that the neuroprotective ability of lubeluzole is unique and involves the direct modulation of the NO pathway. In addition, the mechanisms of NO toxicity are dynamic and reversible processes that, if left unaltered, will lead to neuronal injury. Further investigation of the downstream signal transduction mechanisms below the level of NO generation may elucidate the specific cellular events responsible for neurodegeneration.
Neuronal injury after an ischemic insult is dependent upon the induction of several cellular mechanisms. Activation of specific neuronal pathways (Robertson, 1992) with the eventual loss of cellular calcium homeostasis (Frandsen and Schousboe, 1993) has traditionally been viewed as one of the inciting events of ischemic neuronal cell death. Yet, it is clear that other cellular pathways, in addition to calcium flux, play a role in determining ultimate neuronal survival. Several of these pathways include gene induction (Gubits et al., 1993; Endoh et al., 1994) , neurotransmitter release (Phillis et al., 1994) , cellular metabolism (Pulsinelli and Duffy, 1983; Hashimoto et al., 1992) , and the signal transduction pathways of protein kinase A (PKA), protein kinase C (PKC), and nitric oxide (NO) (Maiese et al., 1993a,b; Maiese, 1994) .
NO is intriguing, not only as one of the downstream modulators of ischemic neuronal injury, but also as a possible therapeutic target. In animal models of focal cerebral ischemia, NO production is increased in the region of infarction (Kuppusamy et al., 1995) . Both pharmacological and genetic in vivo regulation of the neuronal form of nitric oxide synthase (NOS), the enzyme responsible for the production of NO, reduce focal infarct volume (Huang et al., 1994; Nagafuji et al., 1995) . In addition, inhibition of NO production during anoxia in vitro increases neuronal survival (Maiese et al., 1993a) .
Lubeluzole, a novel benzothiazole compound, has recently been demonstrated in clinical trials to be efficacious in reducing mortality after the onset of ischemic stroke (Diener et al., 1996) . In a photochemical stroke model in rats, intravenous posttreatment with lubeluzole stereoselectively rescues neurologic function within a time window of 6 h (De Ryck et al., 1995) . The mechanism of action of lubeluzole is unclear,but the cellularpathways modulated by this agent are not believed to be dependent upon N-methyl-Daspartate (NMDA) receptor blockade (De Ryck et al., 1995) . It is conceivable that lubeluzole functions at a more focused point in the ischemic cascade that is below glutamate release, such as at the level of NO after the generation of this free radical. We have dem-onstrated that agents, such as peptide growth factors, exert their neuroprotective effects through the signal transduction pathways of NO and protein kinases (Maiese et a!., 1993a; . Therefore, we examined whether the neuroprotective mechanisms of lubeluzole were mediated through similar cellular pathways, in an effort to further dissect the cellular processes that are responsible for neurodegeneration.
MATERIALS AND METHODS

Hippocampal cultures
The hippocampi were obtained from 1-day-old SpragueDawley rat pups and incubated in dissociation medium (90 mM Na 2SO4, 30 mM K2SO4, 5.8 mM MgCl2, 0.25 mM CaC12, 10 mM kynurenic acid, and 1 mM HEPES, with pH adjusted to 7.4) containing papain (10 U/ml) and cysteine (3 mmol/L) for two 20-mm periods. The hippocampi were then rinsed in dissociation medium and incubated in dissociation medium containing trypsin inhibitor (10-20 UIml) for three times, 5 mm each. The cells were washed in growth medium (Leibovitz's L-15 medium, GibcoBRL, Gaithersburg, MD, U.S.A.) with 6% sterile rat serum (Bioproducts for Science, Indianapolis, IN, U.S.A.), 150 mM NaHCO3, 2.25 mg/ml transferrin, 2.5~g/ml insulin, 10 nM progesterone, 90 jiM putrescine, 15 nM selenium, 35 mM glucose, 1 mM L-glutamine, penicillin (50 U/mi), and streptomycin (50 jig/ml) and supplemented with vitamins. The dissociated cells were plated at a density of~15 x io~cells! mm 2 in 35-mm polylysine-laminin-coated plates (Falcon Labware, Lincoln Park, NJ, U.S.A.). Cells were maintained in growth medium at 37°Cin a humidified atmosphere of 5% CO 2 and 95% room air. All experiments were performed with cultured neurons that had been in culture for 2 weeks. Nonneuronal cells accounted for <10% of the total cell population.
Experimental treatments
NO administration was performed by replacing the culture media with media containing 300 jiM sodium nitroprusside (SNP) (Sigma Chemical Company, St. Louis, MO, U.S.A.) or 300 jiM 3-morpholinosydnonimine (SIN-i) (Alexis Corporation, San Diego, CA, U.S.A.) for 5 mm. We have previously shown that both SNP and SIN-1 are directly toxic to hippocampal neurons through a mechanism that involves the release of NO (Maiese et al., 1993a) . After treatment with SNP or SIN-i, culture medium was replaced with fresh growth medium and the cultures were placed in a normoxic, humidified incubator at 37°Cwith 5% CO2 for 24 h before assessing neuronal cell death. Lubeluzole and the R-isomer of lubeluzole (R-isomer) were supplied by the Janssen Research Foundation, Beerse, Belgium. All agents were added directly to the cultures. Experimental cultures involving the use of lubeluzole and the R-isomer received replacement of these agents during any growth media changes.
Assessment of neuronal cell death
Hippocampal neuronal injury was determined by brightfield microscopy using a 0.4% trypan blue dye exclusion method 24 h after treatment with SNP, SIN-i, or lubeluzole. Neurons were identified by morphology. The mean survival was determined by counting eight randomly selected nonoverlapping fields without astrocyte growth containing 10-20 neurons (viable + nonviable) in each 35-mm Petri dish. Untreated (control) cultures are assayed in parallel with each study. The mean survival from each culture dish represents an n = 1 determination. Each experiment was replicated six times independently on separate occasions with different cultures.
Statistical analysis
Neuronal survival rate between groups was analyzed statistically by means of ANOVA and unpaired Student's t test.
RESULTS
The neuroprotective effects of lubeluzole are mediated at the level of NO generation
We examined the protective effects of lubeluzole at the level of the signal transduction pathways of NO. Hippocampal neurons were treated with either the NO generator SNP (300 jiM) or SIN-i (300 jiM) for 5 mm. Two separate NO generators were used to ensure that the effects observed on neuronal survival were directly related to the presence of NO. With a 300 jiM concentration of of either SNP or SIN-i, '-~70%of the neurons die over a 24-h period (Maiese et a!., 1993a) . At the time of SNP or SIN-I exposure, we administered increasing doses of lubeluzole (0.3-1,000 nM). Administered alone, lubeluzole slightly decreased neuronal survival from~-~80% (0.3 nM) to 70% at the concentration of 1,000 nM (Fig. 1A) . Increasing concentrations of lubeluzole were protective directly against the toxicity of NO, resulting in an ED50 of 100 nM. For the cultures receiving iubeluzole and SNP, neuronal survival for the lubeluzole concentrations of 500-1,000 nM was statistically different when compared with cultures receiving only lubeluzole or SNP using the unpaired Student's t test with p < 0.001 (Fig. 1A) . Lubeluzole appeared to be slightly more efficacious against the toxicity of SIN-1 with an ED50 of 81 nM. When compared with the neuronal survival for the cultures receiving only lubeluzole or SIN-1, neuronal survival for the lubeluzole concentrations of 250-1,000 nM was statistically different using the unpaired Student's t test with p < 0.001 (Fig. 1A) .
Stereoselective neuroprotection by lubeluzole during NO-induced neurodegeneration
To evaluate whether the neuroprotective effects of lubeluzole against NO toxicity were stereospecific, we determined whether treatment with the R-isomer could alter neuronal survival in the presence of SNP or SIN-1. Administered alone in increasing concentrations (0.3-1,000 nM), the R-isomer was not toxic and neuronal survival remained constant at '-~70% (Fig. 1B) . It is noteworthy that concentrations of the R-isomer at >75 jiM with or without exposure to NO generators were toxic and decreased neuronal survival from '-~70 to 30% (data not shown). In contrast to treatment with lubeluzole, the R-isomer was not protective against the toxic effects of NO. Neuronal survival was~~30% in cultures treated with only SNP or SIN-l. In cultures receiving the R-isomer during exposure to NO, neu-nM). No significant differences in neuronal survival were evident between immediate coapplication of lubeluzole and pretreatment (Fig. 2) .
FIG.
1. Lubeluzole, but not the R-isomer, is neuroprotective at the level of NO toxicity. A: Hippocampal neuronal cultures received increasing concentrations of lubeluzole at the time of a 5-mm exposure of SNP (300~tM)(.), a 5-mm exposure of SIN-1 (300 tiM) (0), or in the absence of NO exposure (LI). B: Hippocampal neuronal cultures received increasing concentrations of the R-isomer at the time of a 5-mm exposure of SNP (300 1iM) (•), a 5-mm exposure of SIN-i (300 j~M)(0), or in the absence of NO exposure (U). Neuronal survival was based on the percentage of the total number of neurons (viable + nonviable) and was determined by trypan blue exclusion 24 h after exposure to SNP or SIN-i or after exposure to lubeluzole or the R-isomer in the absence of NO. Each data point represents the mean and SEM of n = 6 determinations (culture plates) from three to four separate experimental preparations.
ronal survival ranged at '=22-32% (0.3-1,000 nM) (Fig. 1B) . Thus, the neuroprotective effects of lubeluzole during exposure to NO generators appear to be stereospecific.
Lubeluzole actively reverses NO injury rather than preconditioning against neurodegeneration
We examined whether pretreatment with lubeluzole conferred greater protection against NO toxicity over the immediate coapplication of lubeluzole during NO exposure. As previously described, lubeluzole, when administered alone, slightly decreased neuronal survival at the concentration of 1,000 nM (Fig. 2) . Two hours before or at the time of SNP exposure, we administered increasing doses of lubeluzole (0.3-1,000
Posttreatment with lubeluzole rescues neurons exposed to NO
Because clinical trials involve the administration of lubeluzole after the onset of an ischemic event, we evaluated whether administration of this agent was neuroprotective after exposure to NO. Lubeluzole (750 nM) was administered at 2, 4, 6, 12, and 24 h after SNP (300 jiM) or SIN-I (300 jiM) application. Neuronal survival increased from~30% during SNP administration alone to '=60% with the application of lubeluzole 2 and 4 h after exposure to SNP (Fig. 3) . Application of lubeluzole 6 h after SNP exposure resulted in a significant increase in the neuronal survival rate to 56 ±3%. No significant improvement in neuronal survival was evident at the posttreatment periods of 12 or 24 h after SNP exposure (Fig. 3) .
Similar to the posttreatment protection conferred by lubeluzole during SNP administration, lubeluzole administration 2 or 4 h after SIN-i exposure was neuroprotective (Fig. 3) . Neuronal survival increased from '-~30%during SIN-i treatment alone to~60% with lubeluzole administration at 2 or 4 h after SIN-i treatment. Protection at 6 h after SIN-i exposure was poor with neuronal survival equal to 36 ±4%. No significant protection against neuronal degeneration was present with the posttreatment times of 12 or 24 h (Fig. 3) .
FIG. 2.
Lubeluzole actively reverses NO toxicity rather than preconditioning against neuronal injury. Hippocampal neuronal cultures received increasing concentrations of lubeluzole 2 h before a 5-mm exposure of SNP (300 1iM) (•), at the time of a 5-mm exposure of SNP (300 jiM) (0), or in the absence of NO exposure (LI). Neuronal survival was based on the percentage of the total number of neurons (viable + nonviable) and was determined by trypan blue exclusion 24 h after exposure to SNP or SIN-i or after exposure to lubeluzole in the absence of NO. Each data point represents the mean and SEM of n = 6 determinations (culture plates) from three to four separate experimental preparations.
FIG.
3. Posttreatment with lubeluzole increases neuronal survival after the exposure to NO. Hippocampal cultures received lubeluzole (750 nM) 2, 4, 6, i2, or 24 h after SNP (300 jiM) or SIN-i (300 pM) administration. Neuronal survival was based on the percentage of the total number of neurons (viable + nonviable) and was determined by the trypan blue exclusion method. In the absence of SNP or SIN-i exposure or lubeluzole administratmon, the neuronal survival of these control cultures was -80%. Data are mean and SEM values of n = 6 determinations (culture plates) from three to four separate experiments. Results of neuronal survival for the 2-or 4-h groups were statistically different (*) from the 12-and 24-h groups, with p < 0.001, ANOVA. Only the results of neuronal survival for the 6-h group recemving SNP were statistically different (*) from the i2-and 24-h groups, with p < 0.001, ANOVA.
DISCUSSION
Neuronal degeneration may be precipitated at several levels in the ischemic cascade. Initial studies supported the consensus that neuronal injury is closely tied to glutamate release (Rothman and Olney, 1986) , and in several cellular environments, specific glutamate receptors play a significant role in neurodegeneration (Maiese et al., 1995, i996 ). Yet, alternate signal transduction pathways are increasingly being recognized as vital mechanisms that modulate both neuronal development and neuronal death. The free radical NO has clearly been linked to ischemic neurodegeneration in both animal models (Huang et al., 1994) and cell culture systems (Maiese et al., l993a) . The final cellular pathways that lead from the generation of NO to eventual neuronal death are under continual investigation and include the formation of peroxynitrite (Beckman, 1991) , intracellular calcium release (Maiese et al., 1994) , and the modulation of protein kinase activity (Maiese et al., i993b; Maiese, 1994) .
Lubeluzole has been demonstrated to be an effective neuroprotective agent in both animal models and in clinical trials of cerebral ischemia (De Ryck et al., 1995; Diener et al., 1996) . The mechanism of action of this agent is not known but is believed to involve cellular pathways that are exclusive of the NMDA receptor (De Ryck et al., 1995) . Thus, lubeluzole may prevent or reverse neuronal injury by regulating more specific signal transduction pathways that are downstream in the ischemic cascade.
We demonstrate that lubeluzole is protective against NO toxicity and that the agent's ability to increase neuronalsurvival is stereospecific. Application of lubeluzole alone was not toxic to the hippocampal neurons. When lubeluzole was coadministered with an NO generator, neuronal survival increased in a dose-dependent manner from '=30 to 70%. In marked contrast, the Risomer was ineffective at any dose in altering the toxic effects of the NO generators SNP and SIN-i, supporting the premise that protection with lubeluzole is stereospecific.
We were able to further dissect the mechanisms of protection by lubeluzole with a pretreatment paradigm. A 2-h pretreatment with lubeluzole before NO exposure did not significantly increase neuronal survival (Fig. 2) . Our study suggests that the agent protects by acutely modifying toxic cellular pathways rather than preconditioning the neuron before injury. In essence, lubeluzole may alter the progression of neuronal degeneration at or below the level of NO generation and subsequently avert neuronal injury. Recent work by others also suggests that lubeluzole may alter the expression of NOS or one of its cofactors (Lesage et al., 1996) .
Our study also illustrates that a protective window exists for the reversal of the toxic effects of NO. Application of lubeluzole during a period of 4-6 h after NO exposure protects~60% of the neuronal population (Fig. 3) . Our results parallel work using an in vivo photochemical stroke model that demonstrates lubeluzole stereoselective posttreatment protection of sensorimotor function within a time window of 6 h (De Ryck et al., 1996) . These observations provide further insight into the processes that mediate neuronal death after the generation of NO. The subsequent downstream signal transduction pathways appear to remain as fluid rather than fixed processes for at least a brief duration. This period of postprotection is consistent with prior reports of temporary neuronal viability in the region of the cerebral ischemic penumbra (Astrup et al., 1981) and points to possibilities for therapeutic intervention.
NO-induced neuronal injury is dependent upon multiple factors. We have previously shown that the signal transduction pathways of PKC and PKA mediate, at least in part, the detrimental effects of NO toxicity (Maiese et al., 1993b; . In addition, cellular calcium, either as an independent entity or in combination with other signal transduction pathways such as NO and PKC, can lead to subsequent neuronal injury (Maiese et al., i994) . We now demonstrate that the neuroprotective effects of lubeluzole are directly linked to the modulation of the signal transduction pathways ofNO. Our work with pre-and posttreatment paradigms adds new insight into the mechanisms of NO toxicity, suggesting that this is an ongoing, active but reversible process that, if left unchecked, will ultimately lead to neurodegeneration. Yet, it is clear that further investigation is required to isolate the downstream cellular and molecular mechanisms that regulate neuronal survival below the level of NO generation. Future dissection of the mechanisms of action of novel neuroprotective agents, such as lubeluzole, can focus the design of new therapeutic interventions and shed light on the cellular and molecular pathways that ultimately mediate neuronal degeneration.
